March 2021 Content Release Copied

03/31/20212021 ContentContent releasePhysician, Clinical, Admin, Billing

Clinical Profile: Problems

AJCC Staging Updates

This release updates TNM values, Stage Groupings and Template functionality for Cervical Cancer.

Updates

For Lung Cancer, Non-small Cell (NSCLC) the following KRAS gene options are available:

  • KRAS G12 activating mutation
  • Other KRAS mutation
  • Wild type
  • Unknown

The problem group Glioblastoma multiforme (disorder) is added to Brain Cancer (Parent).

Lab Analytes & Panels

Additions

  • ABG panel, POC
  • Acetylcholine receptor binding antibody panel
  • Acetylcholine receptor blocking antibody panel
  • Alveolar O2
  • Alveolar O2 tension grad
  • Alveolar O2 tension ratio
  • Amphiphysin Ab, IFA
  • ANA titer 3
  • ANNA1 (HU) Ab, IFA
  • ANNA2 (RI) Ab, IFA
  • ANNA3 Ab, IFA
  • Anti-Scl-70 Ab (RDL)
  • Anti-Scl-70 Ab (RDL) panel
  • Anti-Sm Ab (RDL) panel
  • Anti-Sm Ab (RDL), units
  • Anti-U1 RNP Ab (RDL) panel
  • Anti-U1 RNP Ab (RDL), units
  • B. henselae Ab IgG panel
  • BCR-ABL1 procedure note
  • Bicarbonate, ABG (POC)
  • BRCAssure comprehensive additional clinical information
  • BRCAssure comprehensive clinical indication
  • BRCAssure comprehensive interpretation
  • BRCAssure comprehensive methods and limitations
  • BRCAssure comprehensive panel
  • BRCAssure comprehensive PDF
  • BRCAssure comprehensive recommendations
  • BRCAssure comprehensive references
  • BRCAssure comprehensive released by
  • BRCAssure comprehensive specimen type
  • CD10 – B-cell
  • CD10 – CD45 dim
  • CD10 – CD45 neg
  • CD10 – granulocytes
  • CD10 – monocytes
  • CD117 – CD45 dim
  • CD117 – CD45 neg
  • CD117 – granulocytes
  • CD117 – lymphocytes
  • CD117 – monocytes
  • CD11c – B-cell
  • CD11c – CD45 dim
  • CD11c – CD45 neg
  • CD11c – granulocytes
  • CD11c – lymphocytes
  • CD11c – monocytes
  • CD13 – CD45 dim
  • CD13 – CD45 neg
  • CD13 – granulocytes
  • CD13 – lymphocytes
  • CD13 – monocytes
  • CD14 – CD45 neg
  • CD14 – granulocytes
  • CD14 – lymphocytes
  • CD14 – monocytes
  • CD16 – CD45 dim
  • CD16 – CD45 neg
  • CD16 – granulocytes
  • CD16 – lymphocytes
  • CD16 – monocytes
  • CD19 – CD45 dim
  • CD19 – CD45 neg
  • CD19 – granulocytes
  • CD19 – lymphocytes
  • CD19 – monocytes
  • CD19 – Plasma Cells
  • CD19+/CD10+ – CD45 dim
  • CD2 – CD45 dim
  • CD2 – CD45 neg
  • CD2 – granulocytes
  • CD2 – monocytes
  • CD2 – T-Cell
  • CD2+CD3+ – lymphocytes
  • CD2+CD3+ – T-Cell
  • CD20 – CD45 dim
  • CD20 – CD45 neg
  • CD20 – lymphocytes
  • CD20 – monocytes
  • CD23 – CD45 dim
  • CD23 – CD45 neg
  • CD23 – lymphocytes
  • CD23 – monocytes
  • CD3 – CD45 dim
  • CD3 – CD45 neg
  • CD3 – granulocytes
  • CD3 – lymphocytes
  • CD3 – monocytes
  • CD3 – T-Cell
  • CD33 – CD45 dim
  • CD33 – CD45 neg
  • CD33 – granulocytes
  • CD33 – lymphocytes
  • CD34 – CD45 dim
  • CD34 – CD45 neg
  • CD34 – granulocytes
  • CD34 – lymphocytes
  • CD34 – monocytes
  • CD38 – CD45 dim
  • CD38 – CD45 neg
  • CD38 – lymphocytes
  • CD38 – monocytes
  • CD38 – Plasma Cells
  • CD4 – CD45 dim
  • CD4 – CD45 neg
  • CD4 – granulocytes
  • CD4 – lymphocytes
  • CD4 – monocytes
  • CD4 – T-Cell
  • CD4+/CD8+ – CD45 dim
  • CD4+/CD8+ – granulocytes
  • CD4+/CD8+ – monocytes
  • CD45 – CD45 dim
  • CD45 – CD45 neg
  • CD45 – granulocytes
  • CD45 – lymphocytes
  • CD45 – monocytes
  • CD45 – Plasma Cells
  • CD5 – B-cell
  • CD5 – CD45 dim
  • CD5 – CD45 neg
  • CD5 – lymphocytes
  • CD5 – monocytes
  • CD56 – CD45 dim
  • CD56 – CD45 neg
  • CD56 – granulocytes
  • CD56 – lymphocytes
  • CD56 – Plasma Cells
  • CD56+CD3- – lymphocytes
  • CD64 – CD45 dim
  • CD64 – CD45 neg
  • CD64 – granulocytes
  • CD64 – lymphocytes
  • CD64 – monocytes
  • CD7 – CD45 dim
  • CD7 – CD45 neg
  • CD7 – lymphocytes
  • CD7 – monocytes
  • CD8 – CD45 dim
  • CD8 – CD45 neg
  • CD8 – lymphocytes
  • CD8 – monocytes
  • Cefotaxime+Clavulanate
  • cefTAZidime susc isolate
  • cefTAZidime+Clavulanate susc isolate
  • Chitotriosidase for Gaucher’s panel
  • CMV PCR procedural note
  • Copper, whole blood, ug/mL
  • Creatine panel, serum
  • CRMP5/CV2 Ab, IFA
  • Delivery system, ABG
  • Epstein Barr Virus early antigen (D) panel, IgG
  • EtG/EtS, urine, LC/MS/MS, qual
  • Ethyl glucuronide, urine, LC/MS/MS
  • Ethyl glucuronide, urine, LC/MS/MS note
  • Ethyl glucuronide, urine, qual
  • Ethyl glucuronide/Ethyl sulfate (EtG/EtS) LC/MS/MS panel
  • Ethyl sulfate, urine, LC/MS/MS
  • Ethyl sulfate, urine, qual
  • Factor VII activity clotting panel
  • Factor VII activity, clotting, %
  • Flow – cell yield
  • Flow (Flow Differential (%)) – CD34+
  • Flow (Flow Differential (%)) – CD45 Dim
  • Flow -specimen viability
  • Giardia Ag panel, stool
  • HBsAg quant, IU/mLHelicobacter pylori antibody panel, IgA
  • Helicobacter pylori antibody panel, IgM
  • Hepatitis BE Ag and Ab panel
  • Hepatitis E Ab panel, IgG
  • Hepatitis E Ab panel, IgM
  • Histiocytes #/100 WBC, body fluid
  • HLA-DR – CD45 dim
  • HLA-DR – CD45 neg
  • HLA-DR – granulocytes
  • HLA-DR – lymphocytes
  • HLA-DR – monocytes
  • IgG subclass 1 panel
  • Immunofixation (IFE) IgA, mg/dL
  • Immunofixation (IFE) IgG, mg/dL
  • Immunofixation (IFE) IgM, mg/dL
  • Immunofixation (IFE) serum panel
  • JAK2 Exons 12-15 mutation analysis PCR panel
  • Kappa – lymphocytes
  • Kappa/Lambda – lymphocytes
  • Kappa/Lambda light chains, free w/ratio, reflex to IFX panel
  • Lambda – lymphocytes
  • Liver-kidney microsomal (LKM) antibody panel
  • M spike alpha 1
  • M spike alpha 2
  • M spike beta 1
  • M spike beta 2
  • M spike gamma 1
  • M spike gamma 2
  • M spike gamma 3
  • M Spike panel
  • Meter number, ABG
  • Multiple Myeloma, daratumumab-specific, immunofixation interpretation
  • Multiple Myeloma, daratumumab-specific, immunofixation panel
  • Myoglobin urine panel
  • Neutrophil band, Ab, cells/uL
  • PCA TR (DNER) Ab, IFA
  • PCA1 (YO) Ab, IFA
  • PCA2 Ab, IFA
  • PEEP, ABG (POC)
  • pH panel, stool
  • pH, stool
  • Posaconazole panel
  • PTH Ab panel
  • Resin T3 uptake, ratio
  • TCO2 (calculated), ABG
  • Tissue IFA observation(s)
  • Toxoplasma gondii PCR qual panel
  • Toxoplasma gondii PCR quant panel
  • Toxoplasma gondii PCR, qual
  • Trypanosoma cruzi Ab IgG panel
  • Tumor necrosis factor-alpha highly sensitive panel
  • User, ABG
  • VDRL panel
  • Vitamin B1 panel, plasma
  • West Nile Virus Ab, IgG, IgM panel
  • West Nile Virus Ab, IgM panel
  • Zonisamide panel

Updates

  • BRCAssure comprehensive result
  • Hepatitis BE antibody, qual
  • IgG, Subclass (total)
  • Immunofixation, serum, interpretation
  • Immunoglobulins A/E/G/M, serum panel
  • Multiple marker panel
  • Paraneoplastic Ab evaluation panel w/Reflex to titer/LB, basic
  • PEEP
  • pH, feces
  • SARS CoV-2 semi-quantitative total Ab, spike panel
  • SARS CoV-2 semi-quantitative total Ab, U/mL
  • Standard Leukemia/Lymphoma bone marrow panel
  • Standard Leukemia/Lymphoma comments, bone marrow
  • T4 panel
  • Von Willebrand factor multimer panel

Additions

  • 2-Deoxy-5-Azacytidine invest IV
  • ASB183/GSK2110183 invest IV
  • Asciminib (ABL001) invest Oral
  • Atezolizumab or Placebo, inj [supplied by sponsor]
  • BEC2/BCG vaccine invest Intradermal
  • Bempegaldesleukin invest IV
  • Bone marrow PSC transplant, allogeneic
  • Bone marrow PSC transplant, autologous
  • Dr. Rastogi’s mouthwash Oral Liquid
  • Encequidar invest Oral
  • Glucometer Lancet Intradermal
  • Glucometer Monitor
  • Glucometer Test Strip
  • Insulin Pen Needle
  • Maltose 10% invest IV
  • Pamiparib invest Oral
  • PF-06946860 invest Subcutaneous
  • RAV12 invest IV
  • Syringe 3mL
  • Syringe w-needle,disposable,3ml
  • Tetrodotoxin invest Subcutaneous
  • Triapin invest IV
  • Zolbetuximab invest IV

Updates

Drug Name Change
AZD1775 invest Oral Added alias Adavosertib invest
Cabotegravir-Rilpivirine IM ER Susp 200 mg/mL-300 mg/mL Added Quick Sigs:

  • 4 mL intramuscularly once
  • 6 mL intramuscularly once
  • 6 mL intramuscularly once
  • CABOTEGRAVIR: Inject 2 mL (400 mg) intramuscularly once monthly
  • RILPIVIRINE: Inject 2 mL (600 mg) intramuscularly once monthly
  • 4 mL intramuscularly once
  • CABOTEGRAVIR: Inject 3 mL (600 mg) intramuscularly once
  • RILPIVIRINE: Inject 3 mL (900 mg) intramuscularly once
  • 6 mL intramuscularly once
  • CABOTEGRAVIR: Inject 3 mL (600 mg) intramuscularly once
  • RILPIVIRINE: Inject 3 mL (900 mg) intramuscularly once
Casirivimab-Imdevimab IV Dose Pack 120 mg/mL-120 mg/mL (EUA) Added Casirivimab-Imdevimab 2,400 mg intravenously Piggyback As Directed; infuse 1,200 mg CASIRIVIMAB and 1,200 mg INDEVIMAB (2,400 mg total dose) together as a SINGLE infusion over at least 60 minutes
DSP-7888 Emulsion invest Intradermal Added alias Ombipepimut-S Emulsion invest
Gallium Ga-68 Dotatoc IV

18.5 MBq to 148 MBq/mL

 Added:

  • 0.1 mCi infuse via intravenous drip once
  • 0.1 mCi infuse via intravenously Infusion (Drip) once
  • 0.1 mCi infuse via intravenously push
GSK3326595 invest Oral Added Form GSK3326595 invest 100 mg Tablet
Levothyroxine Oral Set default Form to 25 mcg tablet orally every day
Lutetium Lu 177 Dotatate IV 10 mCi/mL (370 mBq/mL) Added:

  • 1 mCi intravenously Infusion (Drip) once
  • 1 mCi intravenously Piggyback once
NKTR-214 invest IV Added Quick Sigs:

  • 0.003 mg/kg intravenously every 3 weeks
  • 0.006 mg/kg intravenously every 3 weeks
  • 0.01 mg/kg intravenously every 3 weeks
  • 1.1 mg/kg intravenously every 3 weeks
Radium Ra 223 Dichloride IV Added:

  • 1 mCi once infuse via intravenous drip once
  • 1 mCi once infuse via intravenously Infusion (Drip) once
  • 1 mCi once infuse via intravenously Piggyback once
Vinblastine IV Removed Quick Sigs with Intravenously Push Route

Added Instructions “FATAL IF GIVEN INTRATHECALLY. FOR IV USE ONLY”

Is a vesicant
Vincristine IV
Vinorelbine IV
XMT-1536 invest IV Added Form XMT-1536 invest 80 mg lyophilized powder for recon soln
Drug Name New Maximum Single Dose Rounding Rule
Abatacept Subcutaneous 125 mg
Abatacept Subcutaneous Auto-Injector 125 mg
Alemtuzumab IV 12 mg/1.2 mL 12 mg
Asparaginase (Erwinia chrysanthemi) IV 63000 units
Asparaginase (Erwinia chrysanthemi) IM 63000 units
Bleomycin Intrapleural 60 units
Cisplatin Intra-Arterial None
Deferoxamine IM 1000 mg
Deferoxamine Subcutaneous 1000 mg
Dexrazoxane IV 2000 mg
Doxorubicin Intravesical 150 mg None
Doxorubicin Intra-Arterial 150 mg None
Estramustine Oral 2520 mg/day
Everolimus Oral Suspension 25 mg
Interferon Alfa-2B IV 75 million units
Interferon Alfa-2B Subcutaneous 75 million units
Methotrexate IM None
Methotrexate (PF) IM None
Methotrexate Subcutaneous None
Methotrexate (PF) Subcutaneous None
Methotrexate (PF) Subcutaneous Auto-Injector None 5 mg
Ondansetron (PF) IV 16 mg
Pegaspargase IM 6250 units 50 units
Pegaspargase Subcutaneous 6250 units 50 units
Pegaspargase IV 6250 units 50 units
Sargramostim Subcutaneous 625 mcg
Sargramostim IV 625 mcg
Thiotepa Intravesical None
Tocilizumab Subcutaneous Pen Injector 162 mg
Tofacitinib Oral 10 mg; 20 mg/day
Topotecan Intrathecal None
Vedolizumab IV 300 mg
Vincristine Liposomal IV 5.6 mg 0.1 mg

Regimens

Updates

Vinca Alkaloid IV Push Removal

Based on FDA recommendations, vinca alkaloid orders given by IV push are removed from all McKesson regimen templates with this release on 3/31/2021.

Infection Prophylaxis

To reduce risk for unintentional omission, the Collaborative Care Committee (CCC) voted to include standardized HSV/VZV and PJP prophylaxis in regimens with drugs at high risk for infection. These changes will be made over several months.

Ferumoxytol (Feraheme) Infusion Length

Due to risk for infusion-related reactions, CCC voted to change the Feraheme infusion length from “15 minutes” to “over at least 30 minutes”.

Biosimilars

Added Rituximab-arrx (Riabni) and pegfilgrastim-apgf (Nyvepria) as optional orders in applicable regimen templates.

Diagnosis Regimen Updates

CCC voted to change the regimens for the diagnoses below. Changes include but are not limited to updates to references, infusion instructions, regimen names, premedication templates and number of cycles.

  • All Problems
  • Amyloidosis
  • Basal cell carcinoma
  • Breast Cancer
  • Fallopian Tube Cancer
  • Hepatocellular Carcinoma (HCC)
  • Leukemia, Acute Lymphocytic (ALL)
  • Leukemia, Acute Myeloid (AML)
  • Leukemia, Chronic Lymphocytic (CLL)
  • Leukemia, Chronic Myeloid (CML)
  • Lung Cancer, Non-small Cell (NSCLC)
  • Lung Cancer, Small Cell (SCLC)
  • Lymphoma, Non-Hodgkin (NHL) (Parent)
  • Multiple Myeloma (MM)
  • Ovarian and Primary Peritoneal Cancer
  • Prostate Cancer
  • Squamous Cell Carcinoma

Additions

The following regimens are now available for ordering in the Regimen Library.

  • Anastrozole Q30D (Ovarian)
  • Atezolizumab + Bevacizumab BIOSIMILAR + Paclitaxel + Carboplatin Q21D (Part 1 of 2: Induction)
  • Atezolizumab + Bevacizumab BIOSIMILAR + Paclitaxel + Carboplatin Q21D (Part 2 of 2: Atezolizumab + Bevacizumab Maintenance)
  • Capecitabine D1-14 + Margetuximab-cmkb Q21D
  • Daratumumab IV + Cyclophosphamide PO + Bortezomib + Dexamethasone (CyBorD) Q28D (MM) (Part 1 of 2: C1 Split Dosing)
  • Daratumumab IV + Cyclophosphamide PO + Bortezomib + Dexamethasone (CyBorD) Q28D (Amyloidosis) (Part 1 of 2: C1 Split Dosing)
  • Daratumumab IV + Cyclophosphamide PO + Bortezomib + Dexamethasone (CyBorD) Q28D (Amyloidosis) (Part 1 of 2)
  • Daratumumab IV + Cyclophosphamide PO + Bortezomib + Dexamethasone (CyBorD) Q28D (Amyloidosis) (Part 2 of 2: Daratumumab IV only)
  • Daratumumab IV + Lenalidomide + Bortezomib + Dexamethasone (RVD) Q21D (Part 1 of 2: C1 Split Dosing)
  • Daratumumab IV + Lenalidomide + Bortezomib + Dexamethasone (RVD) Q21D (Part 1 of 2)
  • Daratumumab IV + Lenalidomide + Bortezomib + Dexamethasone (RVD) Q28D (Part 2 of 2: Daratumumab IV + Lenalidomide Maintenance)
  • Darolutamide + Goserelin Q3M
  • Darolutamide + Leuprolide Q3M
  • Eribulin D1,8 + Margetuximab-cmkb Q21D
  • Gemcitabine D1,8 + Margetuximab-cmkb Q21D
  • Letrozole Q30D (Ovarian)
  • Melphalan flufenamide + Dexamethasone D1,8,15,22 Q28D
  • Tepotinib Q30D
  • Trilaciclib Q21D
  • Umbralisib Q30D
  • Vinorelbine D1,8 + Margetuximab-cmkb Q21D

Regimen Inactivations

The following regimens are no longer available for ordering in the Regimen Library.

  • Clofarabine D1-5 (Consolidation) Q28D
  • Fludarabine D1-3 + Cyclophosphamide D1-3 + Rituximab IV (FCR) (NHL) Q28D
  • Fludarabine D1-3 + Cyclophosphamide D1-3 + Rituximab IV f/b SQ (FCR) (NHL) Q28D
  • Rituximab IV + Fludarabine D2-4 + Cyclophosphamide D2-4 + Mitoxantrone D2 Q28D (R-FCM)

Regimen Renames

Previous Name New Name
Fludarabine D1-3 + Cyclophosphamide D1-3 + Rituximab IV (FCR) (CLL) Q28D Fludarabine D1-3 + Cyclophosphamide D1-3 + Rituximab IV (FCR) Q28D (CLL)
Fludarabine D1-3 + Cyclophosphamide D1-3 + Rituximab IV BIOSIMILAR (FCR) (CLL) Q28D Fludarabine D1-3 + Cyclophosphamide D1-3 + Rituximab IV BIOSIMILAR (FCR) Q28D (CLL)
Fludarabine D1-3 + Cyclophosphamide D1-3 + Rituximab IV f/b SQ (FCR) (CLL) Q28D Fludarabine D1-3 + Cyclophosphamide D1-3 + Rituximab IV fb SQ (FCR) Q28D (CLL)
Vitamin B12 Pre-Pemetrexed Vitamin B12 with Pemetrexed

Research

Regimen Additions

To support Data Migration, applicable clinical trial regimens for US Oncology Research are migrated and modified for iKnowMed EHR (Generation 1) customers.

Updates

Vinca Alkaloid IV Push Removal

Based on FDA recommendations, vinca alkaloid orders given by IV push are removed from all McKesson regimen templates with this release on 3/31/2021.

Biosimilars

Added Rituximab-arrx (Riabni) and pegfilgrastim-apgf (Nyvepria) as optional orders in applicable regimen templates.

USOR Clinical Trial Updates

Updated Reference Information Updated Drug Service Order Information Updated Regimen Instructions Other Changes
USOR 16065 X X The following regimen is now available for ordering:

USOR 16065 Umbralisib (TGR-1202) Ramp-Up/Intermittent Dosing
USOR 16104 The following regimen is no longer available for ordering: USOR 16104 Part E SGN-LIV1A D1,8,15 Q21D
USOR 18057 X X X The following regimens are now available for ordering: USOR 18057 Part 2A Arm F BMS-986249 + Nivolumab Q28D

USOR 18057 Part 2B BMS-986249 D1 + Nivolumab D1,29 Q56D
USOR 18097 X X X
USOR 18234 X
USOR 18261 X X Sponsor confirmed use of bevacizumab biosimilars is allowed; The following regimens are now available for ordering:

USOR 18261 Arm C FOLFOX + Bevacizumab BIOSIMILAR USOR 18261 Arm C FOLFIRI + Bevacizumab BIOSIMILAR
USOR 19221 X X X
USOR 20150 X X
USOR 20178 X
USOR 20189 X
USOR 20218 X X
USOR 20297 X X

Billing: HCPCS Code Updates

Medication HCPSC Code
Belantamab mafodotin-blmf, inj J9037 per 0.5 mg
Brexucabtagene autoleucel, inj Q2053 per 68 mL
Cabotegravir-Rilpivirine IM ER Susp 200 mg/mL-300 mg/mL (Cabenuva) J3490 per 4 mL J3490 per 6 mL
Casirivimab/imdevimab, inj Q0243 per 2400 mg
Fluoroestradiol F-18 IV 148 MBq/mL to 3,700 MBq/mL A9591 per 1 mCi
Fremanezumab-vfrm Subcutaneous Auto-Injector J3031 per 1 mg
Gallium Ga-68 Dotatoc IV 18.5 MBq to 148 MBq/mL A9587 per 0.1 mCi
Immune globulin,gamma(igg)slra, inj J1554 per 500 mg
Lutetium Lu 177 Dotatate IV 10 mCi/mL (370 mBq/mL) A9513 per 1 mCi
Margetuximab-cmkb IV J3590 per 250 mg
Melphalan Flufenamide IV J9999 per 20 mg
Mometasone furoate J7402 per 10 mcg
Ondansetron Continuous Subcutaneous Infusion J2405 per 1 mg
Ondansetron (PF) Continuous Subcutaneous Infusion J2405 per 1 mg
Pertuzumab-Trastuzumab-Hy-zzxf Subcutaneous 1200 mg- 600 mg-30,000 unit/15 mL (Phesgo) J9316 per 0.0834 mL

J9316 per 6.67 mg
Pertuzumab-Trastuzumab-Hy-zzxf Subcutaneous 600 mg- 600 mg-20,000 unit/10 mL (Phesgo) J9316 per 0.084 mL

J9316 per 10 mg
Sodium Fluoride F-18 IV 10 mCi to 200 mCi/mL A9580 per 30 mCi
Tafasitamab-cxix, inj J9349 per 2 mg
Trilaciclib IV J3490 per 300 mg
Viltolarsen, inj J1427 per 10 mg